Literature DB >> 29373099

Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.

Miki Horiguchi1, Hajime Uno1, Lee-Jen Wei1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29373099     DOI: 10.1200/JCO.2017.75.9829

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544

2.  Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes.

Authors:  Hajime Uno; Deborah Schrag; Dae Hyun Kim; Dejun Tang; Lu Tian; Hope S Rugo; Lee-Jen Wei
Journal:  JNCI Cancer Spectr       Date:  2019-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.